ADC Therapeutics SA (ADCT) Reports Q4 Loss, Misses Revenue Estimates

分组1 - ADC Therapeutics SA reported a quarterly loss of $0.29 per share, better than the Zacks Consensus Estimate of a loss of$0.35, and an improvement from a loss of $1.03 per share a year ago, resulting in an earnings surprise of 17.14$16.91 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 14.01%, and showing a slight increase from year-ago revenues of $16.79 million [2] - ADC Therapeutics shares have declined approximately 20.6% since the beginning of the year, contrasting with the S&P 500's decline of 2.9% [3] 分组2 - The earnings outlook for ADC Therapeutics is uncertain, with current consensus EPS estimates at -$0.41 on revenues of$20.5 million for the coming quarter, and -$1.47 on revenues of$83.02 million for the current fiscal year [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 28% of over 250 Zacks industries, indicating that the industry outlook can significantly impact stock performance [8]